SCHEMBL1016189

SCHEMBL1016189

O=C(O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.74
HSD17B10 Q99714 2/20 0.74
SERPINE1 P05121 8/20 0.60
AKR1C4 P17516 1/20 0.60
AKR1C3 P42330 1/20 0.60
AKR1C2 P52895 1/20 0.60
AKR1C1 Q04828 1/20 0.60
PPARG P37231 1/20 0.59
PPARA Q07869 1/20 0.59
ALDH1A1 P00352 1/20 0.57
TP53 P04637 1/20 0.57
ACLY P53396 1/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA12 O43570 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
KCNK2 O95069 1/20 0.54
KCNK10 P57789 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7988908 0.85 KDM4E (0.70) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL7045036 0.85 KDM4E (1.00) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL7259309 0.85 KDM4E (0.70) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL29183052 0.85 GRIK1 (0.68) KDM4EALDH1A1
SCHEMBL11604753 0.84 KDM4E (0.68) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL13460162 0.82 KDM4E (0.66) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL9681911 0.82 KDM4E (0.66) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL27331760 0.82 KDM4E (0.66) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL418999 0.82 KDM4E (0.66) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3
SCHEMBL29293884 0.82 KDM4E (0.71) KDM4EHSD17B10SERPINE1AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed
US-4085260-A Powder coating compositions with hydroxy containing acrylic copolymers-I and carboxylic acid or anhydride crosslinking agent FORD MOTOR COMPANY (US) 1978-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 KDM4E 4108/4885HSD17B10 1898/4885SERPINE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.